The stock price of Tharimmune Inc (NASDAQ: THAR) has jumped by 8.02 compared to previous close of 1.54. Despite this, the company has seen a gain of 15.28% in its stock price over the last five trading days. accessnewswire.com reported 2025-06-17 that BRIDGEWATER, NEW JERSEY / ACCESS Newswire / June 17, 2025 / Tharimmune, Inc. (NASDAQ:THAR), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology, today announced significant appointments to its executive leadership and board of directors, reinforcing its commitment to advancing its pipeline and strategic initiatives. The Company is advancing its lead candidate TH104 specifically designed through a buccal film formulation to deliver an opioid antagonist rapidly and predictably.
Is It Worth Investing in Tharimmune Inc (NASDAQ: THAR) Right Now?
Additionally, the 36-month beta value for THAR is 1.09. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for THAR is 2.07M and currently, short sellers hold a 2.16% ratio of that float. The average trading volume of THAR on June 26, 2025 was 108.59K shares.
THAR’s Market Performance
THAR’s stock has seen a 15.28% increase for the week, with a 22.27% rise in the past month and a 13.70% gain in the past quarter. The volatility ratio for the week is 10.10%, and the volatility levels for the past 30 days are at 6.35% for Tharimmune Inc. The simple moving average for the past 20 days is 12.77% for THAR’s stock, with a -12.49% simple moving average for the past 200 days.
THAR Trading at 17.23% from the 50-Day Moving Average
After a stumble in the market that brought THAR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -74.02% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at THAR starting from Gravitas Capital LP, who purchase 337,838 shares at the price of $1.48 back on Jun 20 ’25. After this action, Gravitas Capital LP now owns 732,424 shares of Tharimmune Inc, valued at $500,000 using the latest closing price.
Parikh Sanam, the Director of Tharimmune Inc, purchase 1,000 shares at $1.45 during a trade that took place back on Jun 20 ’25, which means that Parikh Sanam is holding 1,770 shares at $1,450 based on the most recent closing price.
Stock Fundamentals for THAR
The total capital return value is set at 15.51. Equity return is now at value -400.44, with -236.68 for asset returns.
Currently, EBITDA for the company is -12.43 million with net debt to EBITDA at 0.09. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.62.
Conclusion
In conclusion, Tharimmune Inc (THAR) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
